Recent Advances in Biomarkers and Technologies that Support Preventive Medicine, Improved Clinical Outcomes and Value-Based Care
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Laboratory Medicine".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 28
Special Issue Editors
Interests: repurposing big data for clinical research; validating new diagnostic assays
Special Issues, Collections and Topics in MDPI journals
Interests: laboratory medicine; clinical chemistry; aging
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Healthcare is rapidly evolving, empowered by the development of new technology and automation. Clinical laboratories should keep pace with these changes to stay relevant and deliver cost-effective care and improved outcomes. Towards this goal, this Special Issue will focus on new blood-based biomarkers (single and multiplex assays) and technologies that enable early diagnoses, continuous monitoring, automation and easy implementation in rural and underserved areas to deliver value-based care.
Topics include, but are not limited to, the following:
- New biomarkers or panels for the early detection of cancer, brain injury and neurological defects;
- Advancements in fluorescence labeling and detection technologies that facilitate the quan-titation of proteins in lower ranges (below picograms per milliliter);
- Technologies that support the continuous monitoring of electrolytes, lactate, high-sensitivity troponin and other critical markers;
- Near-patient testing platforms that allow both CBC and metabolic panel testing.
Dr. Alagarraju Muthukumar
Dr. Kavithalakshmi Sataranatarajan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- blood biomarkers
- serum/plasma proteins
- biomarkers in diseases
- laboratory medicine
- blood test
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
